Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAVE: weekly nab-paclitaxel versus epirubicin in elderly or unfit women with early breast cancer
2012-004489-17Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jun 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Weekly nab-paclitaxel with Epirubicin (2 arms). Primary endpoint: Disease-free survival. Started Jun 2013; status: completed.
02
Drugs
nab-paclitaxelepirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-004489-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004489-17.